Frequently Asked Questions
The market is segmented based on , By Disease Strains (Bacterial Strains, Viral Strains, and Parasitic Strains), Product Type (Reagent Kits and Sequencing Kits and Equipment), Testing Methods (Immunoassay Testing, Conventional Testing, and Molecular Diagnostic Testing), End-User (Hospitals, Clinics/Medical Centers, Research Institutes, and Diagnostic Laboratories) – Industry Trends and Forecast to 2031.
.
The Global Gastroenteritis Testing Market size was valued at USD 3.99 USD Billion in 2023.
The Global Gastroenteritis Testing Market is projected to grow at a CAGR of 5% during the forecast period of 2024 to 2031.
The major players operating in the market include BD (U.S.), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co. Inc. (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Hainan Poly Co. Ltd (China), WOCKHARDT (India).
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.
